Skip to main content
Top
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Second primary cancer risk - the impact of applying different definitions of multiple primaries: results from a retrospective population-based cancer registry study

Authors: Aishah Coyte, David S Morrison, Philip McLoone

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

There is evidence that cancer survivors are at increased risk of second primary cancers. Changes in the prevalence of risk factors and diagnostic techniques may have affected more recent risks.

Methods

We examined the incidence of second primary cancer among adults in the West of Scotland, UK, diagnosed with cancer between 2000 and 2004 (n = 57,393). We used National Cancer Institute Surveillance Epidemiology and End Results and International Agency for Research on Cancer definitions of multiple primary cancers and estimated indirectly standardised incidence ratios (SIR) with 95% confidence intervals (CI).

Results

There was a high incidence of cancer during the first 60 days following diagnosis (SIR = 2.36, 95% CI = 2.12 to 2.63). When this period was excluded the risk was not raised, but it was high for some patient groups; in particular women aged <50 years with breast cancer (SIR = 2.13, 95% CI = 1.58 to 2.78), patients with bladder (SIR = 1.41, 95% CI = 1.19 to 1.67) and head & neck (SIR = 1.93, 95% CI = 1.67 to 2.21) cancer. Head & neck cancer patients had increased risks of lung cancer (SIR = 3.75, 95% CI = 3.01 to 4.62), oesophageal (SIR = 4.62, 95% CI = 2.73 to 7.29) and other head & neck tumours (SIR = 6.10, 95% CI = 4.17 to 8.61). Patients with bladder cancer had raised risks of lung (SIR = 2.18, 95% CI = 1.62 to 2.88) and prostate (SIR = 2.41, 95% CI = 1.72 to 3.30) cancer.

Conclusions

Relative risks of second primary cancers may be smaller than previously reported. Premenopausal women with breast cancer and patients with malignant melanomas, bladder and head & neck cancers may benefit from increased surveillance and advice to avoid known risk factors.
Appendix
Available only for authorised users
Literature
1.
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.CrossRefPubMed Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.CrossRefPubMed
2.
go back to reference Maddams J, Brewster D, Gavin A, Steward J, Elliott J, Utley M, Moller H: Cancer prevalence in the United Kingdom: estimates for 2008. Br J Cancer. 2009, 101: 541-547. 10.1038/sj.bjc.6605148.CrossRefPubMedPubMedCentral Maddams J, Brewster D, Gavin A, Steward J, Elliott J, Utley M, Moller H: Cancer prevalence in the United Kingdom: estimates for 2008. Br J Cancer. 2009, 101: 541-547. 10.1038/sj.bjc.6605148.CrossRefPubMedPubMedCentral
4.
go back to reference Rutten LJ, Arora NK, Bakos AD, Aziz N, Rowland J: Information needs and sources of information among cancer patients: a systematic review of research (1980–2003). Patient Educ Couns. 2005, 57: 250-261. 10.1016/j.pec.2004.06.006.CrossRefPubMed Rutten LJ, Arora NK, Bakos AD, Aziz N, Rowland J: Information needs and sources of information among cancer patients: a systematic review of research (1980–2003). Patient Educ Couns. 2005, 57: 250-261. 10.1016/j.pec.2004.06.006.CrossRefPubMed
6.
go back to reference Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF: New malignancies among cancer survivors: SEER Cancer Registries, 1973–2000. NIH Publ. No. 05–5302. 2006, Bethesda, MD: National Cancer Institute Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF: New malignancies among cancer survivors: SEER Cancer Registries, 1973–2000. NIH Publ. No. 05–5302. 2006, Bethesda, MD: National Cancer Institute
9.
go back to reference Chen Y, Thompson W, Semenciw R, Mao Y: Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev. 1999, 8: 855-861.PubMed Chen Y, Thompson W, Semenciw R, Mao Y: Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev. 1999, 8: 855-861.PubMed
10.
go back to reference Levi F, Randimbison L, Blanc-Moya R, Maspoli-Conconi M, Rosato V, Bosetti C, La Vecchia C: High constant incidence of second primary colorectal cancer. Int J Cancer. 2013, 132: 1679-1682. 10.1002/ijc.27780.CrossRefPubMed Levi F, Randimbison L, Blanc-Moya R, Maspoli-Conconi M, Rosato V, Bosetti C, La Vecchia C: High constant incidence of second primary colorectal cancer. Int J Cancer. 2013, 132: 1679-1682. 10.1002/ijc.27780.CrossRefPubMed
11.
go back to reference Liu L, Lemmens VE, De Hingh IH, de Vries E, Roukema JA, van Leerdam ME, Coebergh JW, Soerjomataram I: Second primary cancers in subsites of colon and rectum in patients with previous colorectal cancer. Dis Colon Rectum. 2013, 56: 158-168. 10.1097/DCR.0b013e318279eb30.CrossRefPubMed Liu L, Lemmens VE, De Hingh IH, de Vries E, Roukema JA, van Leerdam ME, Coebergh JW, Soerjomataram I: Second primary cancers in subsites of colon and rectum in patients with previous colorectal cancer. Dis Colon Rectum. 2013, 56: 158-168. 10.1097/DCR.0b013e318279eb30.CrossRefPubMed
12.
go back to reference Ibrahim EM, Kazkaz GA, Abouelkhair KM, Al-Mansour MM, Al-Fayea TM, Al-Foheidi M, Bayer AM, Elmasri OA: Increased risk of second lung cancer in hodgkin’s lymphoma survivors: a meta-analysis. Lung. 2013, 191: 117-134. 10.1007/s00408-012-9418-4.CrossRefPubMed Ibrahim EM, Kazkaz GA, Abouelkhair KM, Al-Mansour MM, Al-Fayea TM, Al-Foheidi M, Bayer AM, Elmasri OA: Increased risk of second lung cancer in hodgkin’s lymphoma survivors: a meta-analysis. Lung. 2013, 191: 117-134. 10.1007/s00408-012-9418-4.CrossRefPubMed
13.
go back to reference Jegu J, Binder-Foucard F, Borel C, Velten M: Trends over three decades of the risk of second primary cancer among patients with head and neck cancer. Oral Oncol. 2013, 49: 9-14. 10.1016/j.oraloncology.2012.06.018.CrossRefPubMed Jegu J, Binder-Foucard F, Borel C, Velten M: Trends over three decades of the risk of second primary cancer among patients with head and neck cancer. Oral Oncol. 2013, 49: 9-14. 10.1016/j.oraloncology.2012.06.018.CrossRefPubMed
18.
go back to reference Moser K, Sellars S, Wheaton M, Cooke J, Duncan A, Maxwell A, Michell M, Wilson M, Beral V, Peto R, Richards M, Patnick J: Extending the age range for breast screening in England: pilot study to assess the feasibility and acceptability of randomization. J Med Screen. 2011, 18: 96-102. 10.1258/jms.2011.011065. http://dx.doi.org/10.1258/jms.2011.011065,CrossRefPubMed Moser K, Sellars S, Wheaton M, Cooke J, Duncan A, Maxwell A, Michell M, Wilson M, Beral V, Peto R, Richards M, Patnick J: Extending the age range for breast screening in England: pilot study to assess the feasibility and acceptability of randomization. J Med Screen. 2011, 18: 96-102. 10.1258/jms.2011.011065. http://​dx.​doi.​org/​10.​1258/​jms.​2011.​011065,CrossRefPubMed
19.
go back to reference Groheux D, Espie M, Giacchetti S, Hindie E: Performance of FDG PET/CT in the clinical management of breast cancer. Radiology. 2013, 266: 388-405. 10.1148/radiol.12110853.CrossRefPubMed Groheux D, Espie M, Giacchetti S, Hindie E: Performance of FDG PET/CT in the clinical management of breast cancer. Radiology. 2013, 266: 388-405. 10.1148/radiol.12110853.CrossRefPubMed
21.
go back to reference Adamo MB, Johnson CH, Ruhl JL, Dickie LA: 2012 SEER Program Coding and Staging Manual. NIH Publication number 12–5581. 2012, Bethesda, MD: National Cancer Institute Adamo MB, Johnson CH, Ruhl JL, Dickie LA: 2012 SEER Program Coding and Staging Manual. NIH Publication number 12–5581. 2012, Bethesda, MD: National Cancer Institute
22.
go back to reference IARC/ENCR/IACR Working Group: International rules for multiple primary cancers. Asian Pacific J Cancer Prev. 2005, 6: 104-106. IARC/ENCR/IACR Working Group: International rules for multiple primary cancers. Asian Pacific J Cancer Prev. 2005, 6: 104-106.
23.
go back to reference International Agency for Research on Cancer: International Rules for Multiple Primary Cancers (ICD-O Third Edition). Internal Report No. 2004/02. 2004, Lyon: IARC International Agency for Research on Cancer: International Rules for Multiple Primary Cancers (ICD-O Third Edition). Internal Report No. 2004/02. 2004, Lyon: IARC
25.
go back to reference Brewster D, Muir C, Crichton J: Registration of lung cancer in Scotland: an assessment of data accuracy based on review of medical records. Cancer Causes Control. 1995, 6: 303-310. 10.1007/BF00051405.CrossRefPubMed Brewster D, Muir C, Crichton J: Registration of lung cancer in Scotland: an assessment of data accuracy based on review of medical records. Cancer Causes Control. 1995, 6: 303-310. 10.1007/BF00051405.CrossRefPubMed
26.
go back to reference Brewster D, Muir C, Crichton J: Registration of colorectal cancer in Scotland: an assessment of data accuracy based on review of medical records. Public Health. 1995, 109: 285-292. 10.1016/S0033-3506(95)80206-1.CrossRefPubMed Brewster D, Muir C, Crichton J: Registration of colorectal cancer in Scotland: an assessment of data accuracy based on review of medical records. Public Health. 1995, 109: 285-292. 10.1016/S0033-3506(95)80206-1.CrossRefPubMed
28.
go back to reference Johnson CH, Peace S, Adamo P, Fritz A, Percy-Laurry A, Edwards BK: The 2007 Multiple Primary and Histology Coding Rules. 2007, Bethesda, MD: National Cancer Institute Johnson CH, Peace S, Adamo P, Fritz A, Percy-Laurry A, Edwards BK: The 2007 Multiple Primary and Histology Coding Rules. 2007, Bethesda, MD: National Cancer Institute
29.
go back to reference Dong C, Hemminki K: Second primary neoplasms in 633,964 cancer patients in Sweden, 1958–1996. Int J Cancer. 2001, 93: 155-161. 10.1002/ijc.1317.CrossRefPubMed Dong C, Hemminki K: Second primary neoplasms in 633,964 cancer patients in Sweden, 1958–1996. Int J Cancer. 2001, 93: 155-161. 10.1002/ijc.1317.CrossRefPubMed
31.
go back to reference Crocetti E, Buiatti E, Falini P: Multiple primary cancer incidence in Italy. Eur J Cancer. 2001, 37: 2449-2456. 10.1016/S0959-8049(01)00314-8.CrossRefPubMed Crocetti E, Buiatti E, Falini P: Multiple primary cancer incidence in Italy. Eur J Cancer. 2001, 37: 2449-2456. 10.1016/S0959-8049(01)00314-8.CrossRefPubMed
32.
go back to reference Atienza JA, Dasanu CA: Incidence of second primary malignancies in patients with treated head and neck cancer: a comprehensive review of literature. Curr Med Res Opin. 2012, 28: 1899-1909. 10.1185/03007995.2012.746218.CrossRefPubMed Atienza JA, Dasanu CA: Incidence of second primary malignancies in patients with treated head and neck cancer: a comprehensive review of literature. Curr Med Res Opin. 2012, 28: 1899-1909. 10.1185/03007995.2012.746218.CrossRefPubMed
33.
go back to reference Kellen E, Kiyohara H: Multiple primary cancer (MPC) associated with bladder cancer: an analysis of the clinical and autopsy cases in Japan. Jpn J Clin Oncol. 1985, 15 (S1): 201-210. Kellen E, Kiyohara H: Multiple primary cancer (MPC) associated with bladder cancer: an analysis of the clinical and autopsy cases in Japan. Jpn J Clin Oncol. 1985, 15 (S1): 201-210.
34.
go back to reference Fabbri C, Ravaioli A, Ravaioli A, Bucchi L, Balducci C, Canuti D, Desiderio F, Foca F, Panzini I, Falcini F: Risk of cancer of the prostate and of the kidney parenchyma following bladder cancer. Tumori. 2007, 93: 124-128.PubMed Fabbri C, Ravaioli A, Ravaioli A, Bucchi L, Balducci C, Canuti D, Desiderio F, Foca F, Panzini I, Falcini F: Risk of cancer of the prostate and of the kidney parenchyma following bladder cancer. Tumori. 2007, 93: 124-128.PubMed
35.
go back to reference Mellemkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride ML, Kliewer EV, Tonita JM, Kee-Seng C, Pompe-Kirn V, Martos C, Jonasson JG, Boffetta P, Brennan P: Risk of second cancer among women with breast cancer. Int J Cancer. 2006, 118: 2285-2292. 10.1002/ijc.21651.CrossRefPubMed Mellemkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride ML, Kliewer EV, Tonita JM, Kee-Seng C, Pompe-Kirn V, Martos C, Jonasson JG, Boffetta P, Brennan P: Risk of second cancer among women with breast cancer. Int J Cancer. 2006, 118: 2285-2292. 10.1002/ijc.21651.CrossRefPubMed
37.
go back to reference Schmid-Wendtner MH, Baumert J, Wendtner CM, Plewig G, Volkenandt M: Risk of second primary malignancies in patients with cutaneous melanoma. Br J Dermatol. 2001, 145: 981-985. 10.1046/j.1365-2133.2001.04507.x.CrossRefPubMed Schmid-Wendtner MH, Baumert J, Wendtner CM, Plewig G, Volkenandt M: Risk of second primary malignancies in patients with cutaneous melanoma. Br J Dermatol. 2001, 145: 981-985. 10.1046/j.1365-2133.2001.04507.x.CrossRefPubMed
38.
go back to reference Thellenberg C, Malmer B, Tavelin B, Gronberg H: Second primary cancers in men with prostate cancer: an increased risk of male breast cancer. J Urol. 2003, 169: 1345-1348. 10.1097/01.ju.0000056706.88960.7c.CrossRefPubMed Thellenberg C, Malmer B, Tavelin B, Gronberg H: Second primary cancers in men with prostate cancer: an increased risk of male breast cancer. J Urol. 2003, 169: 1345-1348. 10.1097/01.ju.0000056706.88960.7c.CrossRefPubMed
39.
go back to reference Hemminki K, Li X, Dong C: Second primary cancers after sporadic and familial colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2001, 10: 793-798.PubMed Hemminki K, Li X, Dong C: Second primary cancers after sporadic and familial colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2001, 10: 793-798.PubMed
40.
go back to reference Hemminki K, Aaltonen L, Li X: Subsequent primary malignancies after endometrial carcinoma and ovarian carcinoma. Cancer. 2003, 97: 2432-2439. 10.1002/cncr.11372.CrossRefPubMed Hemminki K, Aaltonen L, Li X: Subsequent primary malignancies after endometrial carcinoma and ovarian carcinoma. Cancer. 2003, 97: 2432-2439. 10.1002/cncr.11372.CrossRefPubMed
Metadata
Title
Second primary cancer risk - the impact of applying different definitions of multiple primaries: results from a retrospective population-based cancer registry study
Authors
Aishah Coyte
David S Morrison
Philip McLoone
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-272

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine